April 30th 2022
By Skylar Jeremias
New information on oncology biosimilars have sprouted during the month of April, including an FDA approval, study results from conferences, and data on pegfilgrastim biosimilar utilization and spending.
April 26th 2022
Although Roche’s earnings report for the first quarter of 2022 showed overall increases, products like Herceptin, Avastin, and Rituxan continue to lose revenue due to biosimilar competition.
April 23rd 2022
Posters from the Academy of Managed Care Pharmacy (AMCP)’s annual meeting highlighted the clinical similarity of a trastuzumab biosimilar compared with its reference product and real-world longitudinal application of infliximab biosimilars.
April 20th 2022
Medicare Part D plans missed out on between $84 million and $143 million in savings by not prioritizing the use of biosimilars over reference products, according to a report from the HHS Office of Inspector General.
April 18th 2022
By Laura Joszt
An analysis of real-world dosing and effectiveness of pegfilgrastim biosimilars found the clinical benefits of preventing febrile neutropenia in patients with intermediate to high risk come at acceptable financial costs compared with filgrastim biosimilars.
April 13th 2022
By Allison Inserro
Amneal said the product, to be sold under the name Alymsys, is the second of 3 US biosimilars the company expects to see approved this year.
By Mary Caffrey
If approved, Celltrion's CT-P16 would be the fourth bevacizumab biosimilar to reach the market.
April 9th 2022
Switzerland-based company Fresenius Kabi announced that its pegfilgrastim biosimilar received marketing authorization in Europe and that it has obtained a majority stake in biosimilar manufacturer mAbxience and acquired its subsidiary.
April 5th 2022
Edward Arrowsmith, MD, discussed his recent paper on the use of clinical pathways for specific cancer types and how biosimilar development can help ensure quality of care for patients with limited therapeutic options.
April 4th 2022
With white bagging, pharmacy benefit managers (PBMs) require certain high-cost drugs to be shipped from their own specialty pharmacies to practices, where clinicians then administer the drugs to patients.
